Oxford BioDynamics Ltd
Oxford BioDynamics Ltd
Bastonini E.,University of Oxford |
Jeznach M.,Oxford BioDynamics Ltd. |
Field M.,Oxford BioDynamics Ltd. |
Juszczyk K.,Oxford BioDynamics Ltd. |
And 9 more authors.
Pigment Cell and Melanoma Research | Year: 2014
The major barrier to effective cancer therapy is the presence of genetic and phenotypic heterogeneity within cancer cell populations that provides a reservoir of therapeutically resistant cells. As the degree of heterogeneity present within tumours will be proportional to tumour burden, the development of rapid, robust, accurate and sensitive biomarkers for cancer progression that could detect clinically occult disease before substantial heterogeneity develops would provide a major therapeutic benefit. Here, we explore the application of chromatin conformation capture technology to generate a diagnostic epigenetic barcode for melanoma. The results indicate that binary states from chromatin conformations at 15 loci within five genes can be used to provide rapid, non-invasive multivariate test for the presence of melanoma using as little as 200 μl of patient blood. © 2014 John Wiley & Sons A/S.
Jakub J.W.,Mayo Medical School |
Grotz T.E.,Mayo Medical School |
Jordan P.,Oxford BioDynamics Ltd |
Hunter E.,Oxford BioDynamics Ltd |
And 4 more authors.
Melanoma Research | Year: 2015
Prognosis is markedly improved when melanoma is diagnosed early. Improved methods are needed for earlier detection and screening. We hypothesized that epigenetic analysis of blood samples could discriminate patients with melanoma from patients with other cutaneous lesions and from healthy volunteers. After institutional review board approval and consent, whole blood was obtained from 59 patients with melanoma, 20 patients with other skin cancers, 20 patients with benign skin conditions, and 20 healthy volunteers. Fifteen conformation biomarkers from five gene loci were analyzed on chromatin with the EpiSwitch technology using a modified chromatin conformation capture assay. Differentiation between patients with melanoma and those with nonmelanoma skin cancers was correct 85% of the time, resulting in a sensitivity of 88% and a specificity of 82%. Differentiation of patients with melanoma from healthy controls was correct 80% of the time, resulting in a sensitivity of 85% and a specificity of 75%. The noninvasive test was more accurate in early-stage melanoma (1/10 and 1/16 stage I and stage II patients were misclassified, respectively) and became less accurate with more advanced disease (3/14 and 4/19 stage III and IV patients were misclassified, respectively). We report the results of a noninvasive test using chromosomal aberrations and epigenetic changes identified in peripheral blood that, in this pilot study, distinguished patients with early-stage melanoma from other cohorts. © 2015 Wolters Kluwer Health, Inc. All rights reserved.
Oxford Biodynamics Ltd | Date: 2010-06-29
Medical testing kits for testing of genetic conditions and diseases comprising a serum transfer tube, biohazard return bag with pocket, absorbent sheet, bubble pocket, integrity seal for the transfer tube, a sterile disposable pipette, plastic test tubes, bottles, reagents, chemicals, enzymes, instruction manuals, technical sheets and safety documents sold as a unit; medical apparatus and instruments for testing of genetic conditions and diseases. Scientific and technological services and research and design relating thereto, namely, research into the development and production of medical testing kits; design and development of computer hardware and software; computer programming; installation, maintenance and repair of computer software; computer consultancy services; design services, namely, providing designs, drawings and commissioned technical writing for the compilation of websites; creating, maintaining and hosting the websites of others; and information and advisory services relating to the foregoing. Medical services; veterinary services; hygienic and beauty care for human beings or animals; dentistry services; medical analysis for the diagnosis and treatment of persons; pharmacy advice; and information and advisory services relating to the foregoing.
Agency: GTR | Branch: Innovate UK | Program: | Phase: Collaborative Research & Development | Award Amount: 849.60K | Year: 2015
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with no blood-based diagnostic or prognostic test available. The current management of ALS is supportive, palliative, and multidisciplinary with the only approved therapy, riluzole, having a modest efficacy. Recent late stage clinical failures are thought in part to be due to the existence of disease subtypes in ALS. Biomarkers, especially those connected to different disease processes, would be valuable for stratifying individuals in trial recruitment and to measure treatment effect within each group. OBD and partners are seeking to validate a panel of epigenetic markers, obtained through earlier research, to enable the development of a diagnostic and prognostic test for ALS. This test will enable the stratification of ALS patients with fast vs. slow progressing disease for use as a companion test for novel targeted therapeutic approaches, as a trial selection tool and indicator of treatment efficacy. Additionally the test will have value as a standalone prognostic to inform the wider clinical management of patients.
Oxford Biodynamics Ltd | Date: 2013-06-20
The present invention relates to a method of monitoring epigenetic changes comprising monitoring changes in conditional long range chromosomal interactions at at least one chromosomal locus where the spectrum of long range interaction is associated with a specific physiological condition, the method comprising the steps of: